Search Results 21-30 of 31086 for Two-phase

  1. The Mayo Clinic Diet: A weight-loss program for life

    The Mayo Clinic Diet has two phases: Lose It! This two-week phase is designed to jump-start your weight loss, so you may lose up to 6 to 10 pounds ...

  2. A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction - Mayo Clinic

    This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack ( ...

  3. Phase 2 Study of TAK-341 for Multiple System Atrophy - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on l Unified Multiple ...

  4. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

    The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), and in patients who ...

  5. A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors - Mayo Clinic

    ... Phase 2 dose for evaluation in these patients. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...

  6. A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - Mayo Clinic

    This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen ...

  7. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)- ...

  8. Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis - Mayo Clinic

    This trial consists of two phases: 16 weeks of double-blind treatment and 24 weeks of open-label extension. Participation eligibility. Participant eligibility ...

  9. Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies - Mayo Clinic

    Phase 2 (stage 1): To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the ...

  10. A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis - Mayo Clinic

    PRM-151 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is ...